The ceiling effect of intranasal dexmedetomidine in children

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015326

Enrollment

Unknown

Registered

2018-03-23

Start date

2018-03-28

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemangioma

Interventions

three:Different dosages of dexmedetomidine

Eligibility

Sex/Gender

All

Age

No minimum to 3 Years

Inclusion criteria

Inclusion criteria: Children aged 0–3 years with a diagnosis of hemangioma who required general anesthesia were recruited.

Exclusion criteria

Exclusion criteria: Exclusion criteria included known allergy or hypersensitivity to dexmedetomidine, renal or hepatic dysfunction, nasal discharge, or rhinorrhea.

Design outcomes

Primary

Measure	Time frame
plasma concentration;	—

Secondary

Measure	Time frame
blood pressure;spo2;heart rate;	—

Countries

China

Contacts

Public ContactBilian Li

Guangzhou Women and Children's Medical Centre

13570226780@126.com+86 13570226780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026